Saudi Central Bank Increases Position in Eli Lilly and Company $LLY

Posted by Trevor Kearing on Sep 9th, 2026

Eli Lilly and Company logo Saudi Central Bank raised its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 89.5% in the second quarter, HoldingsChannel reports. The institutional investor owned 56,217 shares of the company’s stock after buying an additional 26,556 shares during the quarter. Eli Lilly and Company makes up approximately 0.9% of Saudi Central Bank’s portfolio, making the stock its 24th biggest holding. Saudi Central Bank’s holdings in Eli Lilly and Company were worth $67,428,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of LLY. BlackRock Inc. boosted its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp raised its position in Eli Lilly and Company by 1.8% during the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after acquiring an additional 635,358 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after purchasing an additional 407,166 shares in the last quarter. Capital World Investors increased its stake in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Eli Lilly and Company by 10.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,123.60 on Wednesday. Eli Lilly and Company has a 1 year low of $712.05 and a 1 year high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The firm has a 50 day moving average price of $1,188.61 and a 200 day moving average price of $1,071.38. The company has a market cap of $1.06 trillion, a price-to-earnings ratio of 37.70, a PEG ratio of 1.42 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 23.22%.

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by insiders.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: The FDA’s approval of Mounjaro to reduce the risk of heart attack or stroke in certain adults with type 2 diabetes could expand the drug’s addressable market and support Lilly’s next phase of growth. Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
Positive Sentiment: Analyst sentiment remains favorable, with Lilly’s average brokerage recommendation signaling optimism about its growth outlook, although such ratings can be biased toward positive recommendations. Wall Street Bulls Look Optimistic About Lilly
Positive Sentiment: Lilly is expanding its neuroscience pipeline through internal development and acquisitions, offering potential long-term growth beyond its diabetes and obesity franchise. Lilly Builds Neuroscience into a New Long-Term Growth Driver
Positive Sentiment: Recent acquisitions could strengthen Lilly’s pipeline and diversify its future revenue base, though investors are assessing whether the deals will justify their cost. Eli Lilly Has Been on an Acquisition Spree
Neutral Sentiment: Lilly’s strong GLP-1 growth remains the central investment thesis, but investors are also focused on increasing competition and the eventual impact of patent expirations for Mounjaro, Zepbound and related products. Lilly’s Acquisition Strategy and GLP-1 Competition
Negative Sentiment: Novartis’ failure in a closely watched cardiovascular trial for an Lp(a)-lowering cholesterol drug pressured the broader drug class and raised concerns about clinical and commercial risk for companies pursuing similar opportunities, including Lilly. Eli Lilly Stock Falls on Novartis Cholesterol Drug Setback
Negative Sentiment: The stock faced broader healthcare-sector selling and a technical breakdown, which intensified the pullback despite Lilly’s favorable long-term fundamentals. Why Is Eli Lilly Stock Falling Tuesday?
Negative Sentiment: Novo Nordisk’s positive pediatric semaglutide study highlights continued competitive progress in obesity treatment, potentially increasing pressure on Lilly’s GLP-1 franchise. Novo Nordisk’s Semaglutide Meets Goal in Pediatric Obesity Study

Analyst Ratings Changes

LLY has been the subject of several recent research reports. Morgan Stanley reissued an “overweight” rating and set a $1,419.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 6th. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Finally, Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,292.18.

View Our Latest Stock Report on Eli Lilly and Company

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.